We are recruiting patients for the CVHB937A12201 Study

The CVHB937A12201 Study is a Phase 2, randomized, placebo-controlled, parallel group study evaluating the efficacy and safety of an investigational study drug, VHB937, for people with mild Alzheimer's disease (AD). This study will include about 400 participants worldwide. Participation could last for up to 7.5 years, which includes an open-label extension of between 96 weeks and 6 years.

Currently approved "symptomatic treatments" for AD are generally well tolerated and can improve symptoms. However, these symptomatic treatments do not change the disease course in people with AD. More recently approved anti-amyloid treatments have safety risks, and only a small number of people are eligible for these treatments.[1] There remains a need for other therapeutic options for the treatment of people with AD.

Preclinical experimental evidence indicates that the effects of VHB937 (a triggering receptor expressed on myeloid cells 2 (TREM2)-selective activator) on TREM2 cell surface expression might attenuate the disease course across neurodegenerative disorders.[2]

Participation involves:

- Study visits every 4 weeks.
- A 72-week double-blind treatment period – VHB937 or placebo.
- An open-label extension, lasting between 96 weeks and 6 years.

We are looking for people who are 50–85 years of age and have:

- A diagnosis of mild cognitive impairment due to AD or mild AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
- A Clinical Dementia Rating global score of 0.5 or 1.0 at screening and baseline.
- A reliable study partner who spends sufficient time with the participant on a regular basis, and is willing and able to attend study visits and answer questions about the participant.

And who do not have:

- Dementia due to a condition other than AD.
- Prior or current treatment with an anti-amyloid antibody, such as lecenemab.
- Stroke or transient ischemia attack in the past 12 months.

Please note that there are additional requirements for taking part.

We would be very grateful if you would consider referring any patients (with their permission) who may be eligible for participation in the CVHB937A12201 Study.

Diversity among our clinical study participants is important to assess risk/benefit ratios for different groups. We request your help in considering the referral of patients who reflect the population of people with AD.

If you have any questions or would like to discuss the referral of a patient, please contact us.

The CVHB937A12201 Study Team

MARY S. EASTON CENTER
for Alzheimer's Research and Care at UCLA
DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA
(310) 794 - 6191

CVHB937A12201